Methylprednisolone Alternatives Compared
| Methylprednisolone | Xolair (omalizumab) | Montelukast |
|
|---|
| Methylprednisolone | Xolair (omalizumab) | Montelukast |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Methylprednisolone effectively controls inflammation and an overactive immune system but may not be suitable for everybody. Long-term use is limited by potentially severe side effects such as... View more |
Prescription only
Xolair is an injectable preparation that works by preventing IgE from binding to IgE receptors on mast cells and basophils and may be used to treat allergic asthma, nasal polyps, chronic idiopathic... View more |
Prescription only
Montelukast is an oral medication that is usually taken daily for the maintenance treatment of asthma or allergic rhinitis. It will not relieve an acute asthma attack and some people may experience... View more |
Related suggestions Asthma, Maintenance
|
|||||||||||||||
| More about Methylprednisolone | More about Xolair (omalizumab) | More about Montelukast | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Methylprednisolone has an average rating of 7.1 out of 10 from a total of 485 ratings on Drugs.com. 63% of reviewers reported a positive effect, while 24% reported a negative effect. |
Xolair has an average rating of 7.5 out of 10 from a total of 229 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 18% reported a negative effect. |
Montelukast has an average rating of 5.6 out of 10 from a total of 571 ratings on Drugs.com. 42% of reviewers reported a positive effect, while 41% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
View all Methylprednisolone side effects |
View all Xolair side effects |
View all Montelukast side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
Lower cost generic |
N/A |
Lower cost generic |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Methylprednisolone prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Montelukast prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Depo-Medrol, Medrol, Medrol Dosepak, MethylPREDNISolone Dose Pack, Solu-Medrol | Other omalizumab brands include: Omlyclo | Singulair | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
3.5 hours |
624 hours |
5.5 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category C
Risk cannot be ruled out
Excluding First Trimester
Category D
Positive evidence of risk
First Trimester See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 625 drugs are known to interact with Methylprednisolone:
|
A total of 29 drugs are known to interact with Xolair:
|
A total of 116 drugs are known to interact with Montelukast:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
|
||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
October 24, 1957 |
June 20, 2003 |
N/A |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
|
||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.